Get the Stockscreener App
4.265
4.32%
-0.185
Humacyte Inc stock is traded at $4.265, with a volume of 1.54M.
It is down -4.32% in the last 24 hours and down -21.01% over the past month.
Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions.
See More
Previous Close:
$4.45
Open:
$4.45
24h Volume:
1.54M
Relative Volume:
0.52
Market Cap:
$572.57M
Revenue:
-
Net Income/Loss:
$-110.78M
P/E Ratio:
-4.9023
EPS:
-0.87
Net Cash Flow:
$-75.59M
1W Performance:
-3.89%
1M Performance:
-21.01%
6M Performance:
-42.23%
1Y Performance:
+60.06%
1-Day Range:
$4.175
$4.49
1-Week Range:
$4.175
$4.74
52-Week Range:
$2.4512
$9.97
Humacyte Inc Stock (HUMA) Company Profile
Name
Humacyte Inc
Sector
Industry
Phone
919-313-9633
Address
2525 EAST NORTH CAROLINA HIGHWAY 54, DURHAM
Compare HUMA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HUMA
Humacyte Inc
|
4.26 | 572.57M | 0 | -110.78M | -75.59M | -1.07 |
|
VRTX
Vertex Pharmaceuticals Inc
|
461.10 | 119.71B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
753.00 | 82.77B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
616.82 | 37.02B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.28 | 32.26B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.28 | 28.24B | 3.30B | -501.07M | 1.03B | -2.1146 |
Humacyte Inc Stock (HUMA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-11-23 | Initiated | H.C. Wainwright | Buy |
| Aug-14-23 | Upgrade | Piper Sandler | Underweight → Neutral |
| Jun-22-23 | Initiated | Cantor Fitzgerald | Overweight |
| May-16-22 | Downgrade | Piper Sandler | Overweight → Underweight |
| Oct-29-21 | Initiated | Cowen | Outperform |
| Sep-24-21 | Initiated | Oppenheimer | Outperform |
| Sep-22-21 | Initiated | BTIG Research | Buy |
| Sep-16-21 | Initiated | Piper Sandler | Overweight |
View All
Humacyte Inc Stock (HUMA) Latest News
Kirby McInerney LLP Reminds Humacyte (HUMA) Investors of Class Action Filing and Encourages Investors to Contact the Firm - Business Wire
HUMA Investors Have Opportunity to Lead Humacyte, Inc. Securities Fraud Lawsuit - PR Newswire
Humacyte’s (HUMA) Statements to Investors Called Into Question in Light of FDA Violations – Hagens Berman - GlobeNewswire
HUMACYTE, INC. (NASDAQ: HUMA) DEADLINE ALERT: Bernstein - GlobeNewswire
Humacyte to Present at the Piper Sandler 36th Annual Healthcare Conference - The Manila Times
Shareholders of Humacyte, Inc. Should Contact Levi & Korsinsky Before January 17, 2025 to Discuss Your RightsHUMA - PR Newswire
ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Humacyte, Inc. Investors to Secure Counsel - The Bakersfield Californian
ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Humacyte, - GlobeNewswire
ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Humacyte, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Humacyte - Markets Insider
HUMA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Humacyte, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - PR Newswire
HUMA Investors Have Opportunity to Lead Humacyte, Inc. Securities Fraud Lawsuit with the Schall Law Firm - Lelezard
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Humacyte, Inc. Investors to Secure - The Bakersfield Californian
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Humacyte, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
HUMA Investors Have Opportunity to Lead Humacyte, Inc. Securities Fraud Lawsuit - Benzinga
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Humacyte - AccessWire
Finansavisen - Finansavisen
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Humacyte - GlobeNewswire
Kirby McInerney LLP Reminds Humacyte, Inc. (HUMA) Investors - GlobeNewswire
The Gross Law Firm Reminds Humacyte, Inc. Investors of the - GlobeNewswire
HUMA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
HUMA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Humacyte, Inc. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit! - AccessWire
HUMA LAWSUIT ALERT: Levi Korsinsky Notifies Humacyte, Inc. | Trending From Our Network - Chicago Star Media
HUMA STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Humacyte, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - AccessWire
HUMACYTE ALERT: Bragar Eagel & Squire, P.C. Announces that - GlobeNewswire
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Humacyte, Inc.- HUMA - PR Newswire
Humacyte, Inc. Class Action Lawsuit Alert: Johnson Fistel - GlobeNewswire
Humacyte (HUMA) Faces Class Action Lawsuit After FDA Inspection Reveals Manufacturing Issues – Hagens Berman - GlobeNewswire
Glancy Prongay & Murray LLP Reminds Investors of Looming - GlobeNewswire
Humacyte (NASDAQ:HUMA) Given Buy Rating at D. Boral Capital - MarketBeat
HUMA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Humacyte, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - AccessWire
Humacyte, Inc. (NASDAQ:HUMA) Receives $11.00 Average Target Price from Analysts - MarketBeat
Humacyte, Inc. Shareholder Alert: Robbins LLP Reminds Investors of the HUMA Securities Class Action - GlobeNewswire
HUMA DEADLINE: Investors Are Encouraged to Contact Kaplan Fox Before January 17, 2025 - The Globe and Mail
Faruqi & Faruqi Reminds Humacyte Investors of the Pending Class Action Lawsuit with a Lead - The Bakersfield Californian
Faruqi & Faruqi Reminds Humacyte Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 17, 2025 – HUMA - Morningstar
Humacyte to Present Efficacy and Safety Results from V007 Phase 3 AV Access Clinical Trial at the 51st Annual Symposium on Vascular and Endovascular Issues, Techniques and Horizons (VEITH) - The Manila Times
Humacyte sees success in dual emergency-engineered tissue trials - Yahoo Finance
HUMA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Humacyte, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - AccessWire
The Gross Law Firm Announces the Filing of a Securities Class Ac - GuruFocus.com
The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Humacyte, Inc.(HUMA) Shareholders - Marketscreener.com
HUMA Deadline to Lead in Securities Fraud Lawsuit is January 17, 2025Contact Kaplan Fox & Kilsheimer LLP - The Globe and Mail
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Humacyte, Inc. (HUMA) - Business Wire
Humacyte director Brady Dougan buys $7,978 in common stock - Investing.com India
ROSEN, LEADING INVESTOR COUNSEL, Encourages Humacyte, Inc. - GlobeNewswire
HUMACYTE, INC. (NASDAQ: HUMA) INVESTOR ALERT: Investors - GlobeNewswire
Insider Buyers At Humacyte Likely Disappointed With 17% Slide - Yahoo Finance
HUMA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Humacyte, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit! - AccessWire
Humacyte Inc Stock (HUMA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.09%
0.92%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):